Literature DB >> 15481438

Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Tomohiro Kinoshita1.   

Abstract

A number of genetic alterations are involved in the development of hematologic malignancies. These alterations include the activation of oncogenes by chromosomal translocation or gene amplification and the inactivation of tumor suppressor genes by gene deletion or mutations. Recently, epigenetic change has been proven to be another important means of inactivating tumor suppressor genes in tumor cells, and hypermethylation of promoter DNA is one of the most important mechanisms. In hematologic malignancies, many kinds of tumor suppressor genes and candidate suppressor genes are epigenetically inactivated. Inactivation of tumor suppressor genes usually occurs in a disease-specific manner and plays important roles in the development and progression of the disease. Some of these alterations have clinical effects on treatment results or the prognoses of the patients.

Entities:  

Mesh:

Year:  2004        PMID: 15481438     DOI: 10.1532/ijh97.04056

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  170 in total

1.  HIC1 hypermethylation is a late event in hematopoietic neoplasms.

Authors:  J P Issa; B A Zehnbauer; S H Kaufmann; M A Biel; S B Baylin
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

2.  Prognostic implications of epigenetic silencing of p15INK4B in acute promyelocytic leukemia.

Authors:  Guillermo Garcia-Manero
Journal:  Leukemia       Date:  2003-05       Impact factor: 11.528

3.  p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance.

Authors:  G Guillerm; E Gyan; D Wolowiec; T Facon; H Avet-Loiseau; K Kuliczkowski; F Bauters; P Fenaux; B Quesnel
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

Review 4.  Tumor suppressor genes in normal and malignant hematopoiesis.

Authors:  Utz Krug; Arnold Ganser; H Phillip Koeffler
Journal:  Oncogene       Date:  2002-05-13       Impact factor: 9.867

5.  Cancer-specific region of hypermethylation identified within the HIC1 putative tumour suppressor gene in acute myeloid leukaemia.

Authors:  J R Melki; P C Vincent; S J Clark
Journal:  Leukemia       Date:  1999-06       Impact factor: 11.528

6.  Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance.

Authors:  C S Chim; R Liang; C Y Tam; Y L Kwong
Journal:  J Clin Oncol       Date:  2001-04-01       Impact factor: 44.544

7.  Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Maria Teresa Voso; Alessandra Scardocci; Francesco Guidi; Gina Zini; Antonella Di Mario; Livio Pagano; Stefan Hohaus; Giuseppe Leone
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

8.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

Review 9.  Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg.

Authors:  Manel Esteller
Journal:  Clin Immunol       Date:  2003-10       Impact factor: 3.969

10.  Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival.

Authors:  Maria V Mateos; Ramón García-Sanz; Ricardo López-Pérez; Maria J Moro; Enrique Ocio; Jose Hernández; Marta Megido; Maria D Caballero; Javier Fernández-Calvo; Abelardo Bárez; Julia Almeida; Alberto Orfão; Marcos González; Jesús F San Miguel
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

View more
  2 in total

1.  Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma.

Authors:  Toshihito Ohno; Junji Hiraga; Haruhiko Ohashi; Chiho Sugisaki; Eika Li; Haruhiko Asano; Tastuya Ito; Hirokazu Nagai; Yoriko Yamashita; Naoyoshi Mori; Tomohiro Kinoshita; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

2.  Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia.

Authors:  Hui Yang; Hui Liang; Jing-song Yan; Rong Tao; Si-guo Hao; Li-yuan Ma
Journal:  Int J Hematol       Date:  2012-06-07       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.